JP2012525426A - うつ病を治療する方法 - Google Patents
うつ病を治療する方法 Download PDFInfo
- Publication number
- JP2012525426A JP2012525426A JP2012508732A JP2012508732A JP2012525426A JP 2012525426 A JP2012525426 A JP 2012525426A JP 2012508732 A JP2012508732 A JP 2012508732A JP 2012508732 A JP2012508732 A JP 2012508732A JP 2012525426 A JP2012525426 A JP 2012525426A
- Authority
- JP
- Japan
- Prior art keywords
- depression
- viloxazine
- day
- activity
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000694 effects Effects 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 23
- 102000005962 receptors Human genes 0.000 claims abstract description 22
- 108020003175 receptors Proteins 0.000 claims abstract description 22
- 239000008177 pharmaceutical agent Substances 0.000 claims abstract description 11
- 230000002474 noradrenergic effect Effects 0.000 claims abstract description 7
- 230000000862 serotonergic effect Effects 0.000 claims abstract description 3
- 229960001255 viloxazine Drugs 0.000 claims description 33
- YWPHCCPCQOJSGZ-LLVKDONJSA-N (2r)-2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OC[C@@H]1OCCNC1 YWPHCCPCQOJSGZ-LLVKDONJSA-N 0.000 claims description 32
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 229940076279 serotonin Drugs 0.000 claims description 9
- 239000013543 active substance Substances 0.000 claims description 6
- 230000001270 agonistic effect Effects 0.000 claims description 6
- 230000003042 antagnostic effect Effects 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims description 5
- 230000002411 adverse Effects 0.000 claims description 5
- 230000005764 inhibitory process Effects 0.000 claims description 5
- 229960002748 norepinephrine Drugs 0.000 claims description 5
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims description 5
- 101710150237 5-hydroxytryptamine receptor 7 Proteins 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- 238000007423 screening assay Methods 0.000 claims description 3
- 208000020401 Depressive disease Diseases 0.000 claims description 2
- 230000003291 dopaminomimetic effect Effects 0.000 claims description 2
- 230000003371 gabaergic effect Effects 0.000 claims description 2
- 230000002295 serotoninergic effect Effects 0.000 claims description 2
- 108010078791 Carrier Proteins Proteins 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102000040811 transporter activity Human genes 0.000 claims 1
- 108091092194 transporter activity Proteins 0.000 claims 1
- 239000000556 agonist Substances 0.000 description 12
- 238000003556 assay Methods 0.000 description 9
- 239000005557 antagonist Substances 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 108091005436 5-HT7 receptors Proteins 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- HJOCKFVCMLCPTP-UHFFFAOYSA-N 2-[(2-ethoxyphenoxy)methyl]morpholine;hydron;chloride Chemical compound Cl.CCOC1=CC=CC=C1OCC1OCCNC1 HJOCKFVCMLCPTP-UHFFFAOYSA-N 0.000 description 2
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 206010010305 Confusional state Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010013887 Dysarthria Diseases 0.000 description 2
- 102000014630 G protein-coupled serotonin receptor activity proteins Human genes 0.000 description 2
- 206010024421 Libido increased Diseases 0.000 description 2
- 208000001089 Multiple system atrophy Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010031127 Orthostatic hypotension Diseases 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 102000002852 Vasopressins Human genes 0.000 description 2
- 108010004977 Vasopressins Proteins 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 208000014987 limb edema Diseases 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000000611 regression analysis Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960003726 vasopressin Drugs 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- YWPHCCPCQOJSGZ-UHFFFAOYSA-N 2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OCC1OCCNC1 YWPHCCPCQOJSGZ-UHFFFAOYSA-N 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 101000744211 Homo sapiens 5-hydroxytryptamine receptor 7 Proteins 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 101710196023 Vicilin Proteins 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000001022 anti-muscarinic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003491 cAMP production Effects 0.000 description 1
- 231100000457 cardiotoxic Toxicity 0.000 description 1
- 230000001451 cardiotoxic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 150000002780 morpholines Chemical class 0.000 description 1
- 230000010004 neural pathway Effects 0.000 description 1
- 210000000118 neural pathway Anatomy 0.000 description 1
- 230000000966 norepinephrine reuptake Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229960005014 viloxazine hydrochloride Drugs 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17408409P | 2009-04-30 | 2009-04-30 | |
| US61/174,084 | 2009-04-30 | ||
| PCT/US2010/032974 WO2010127120A1 (en) | 2009-04-30 | 2010-04-29 | Method of treatment of depression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014170572A Division JP2014240417A (ja) | 2009-04-30 | 2014-08-25 | うつ病を治療する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012525426A true JP2012525426A (ja) | 2012-10-22 |
| JP2012525426A5 JP2012525426A5 (https=) | 2013-06-20 |
Family
ID=43032555
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012508732A Pending JP2012525426A (ja) | 2009-04-30 | 2010-04-29 | うつ病を治療する方法 |
| JP2014170572A Pending JP2014240417A (ja) | 2009-04-30 | 2014-08-25 | うつ病を治療する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014170572A Pending JP2014240417A (ja) | 2009-04-30 | 2014-08-25 | うつ病を治療する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20120115871A1 (https=) |
| EP (1) | EP2424539A4 (https=) |
| JP (2) | JP2012525426A (https=) |
| AU (1) | AU2010242971A1 (https=) |
| CA (1) | CA2760527A1 (https=) |
| CO (1) | CO6470848A2 (https=) |
| MX (1) | MX2011011579A (https=) |
| WO (1) | WO2010127120A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2341912B1 (en) | 2008-09-05 | 2014-01-22 | Supernus Pharmaceuticals, Inc. | Method of treatment of attention deficit/hyperactivity disorder (adhd) |
| AU2013217013B2 (en) | 2012-02-08 | 2017-04-20 | Supernus Pharmaceuticals, Inc. | Modified release formulations of viloxazine |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4260606A (en) * | 1979-07-19 | 1981-04-07 | A. H. Robins Company, Inc. | 3-Methyleneazetidine derivatives |
| DE19830201A1 (de) * | 1998-07-07 | 2000-01-13 | Boehringer Ingelheim Pharma | Mittel mit antidepressiver Wirkung |
| WO2000006162A1 (de) * | 1998-07-27 | 2000-02-10 | Boehringer Ingelheim Pharma Kg | Mittel mit antidepressiver wirkung, mit pramipexol und einem weiteren antidepressivum |
| JP2004517112A (ja) * | 2001-01-02 | 2004-06-10 | ファルマシア・アンド・アップジョン・カンパニー | 新規薬物コンビネーション |
| AU2007260356B2 (en) * | 2006-06-16 | 2013-01-24 | H. Lundbeck A/S | Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain |
| EP2341912B1 (en) * | 2008-09-05 | 2014-01-22 | Supernus Pharmaceuticals, Inc. | Method of treatment of attention deficit/hyperactivity disorder (adhd) |
-
2010
- 2010-04-29 JP JP2012508732A patent/JP2012525426A/ja active Pending
- 2010-04-29 WO PCT/US2010/032974 patent/WO2010127120A1/en not_active Ceased
- 2010-04-29 CA CA2760527A patent/CA2760527A1/en not_active Abandoned
- 2010-04-29 US US13/318,007 patent/US20120115871A1/en not_active Abandoned
- 2010-04-29 EP EP10770332A patent/EP2424539A4/en not_active Withdrawn
- 2010-04-29 MX MX2011011579A patent/MX2011011579A/es not_active Application Discontinuation
- 2010-04-29 AU AU2010242971A patent/AU2010242971A1/en not_active Abandoned
-
2011
- 2011-11-30 CO CO11165136A patent/CO6470848A2/es not_active Application Discontinuation
-
2014
- 2014-08-25 JP JP2014170572A patent/JP2014240417A/ja active Pending
Non-Patent Citations (2)
| Title |
|---|
| JPN5012012263; ＢＡＹＬＩＳＳ: 'ＢＬＯＯＤ ＬＥＶＥＬ ＳＴＵＤＩＥＳ ＷＩＴＨ ＶＩＬＯＸＡＺＩＮＥ ＨＹＤＲＯＣＨＬＯＲＩＤＥ ＩＮ ＭＡＮ' ＢＲ．Ｊ．ＣＬＩＮ．ＰＨＡＲＭＡＣＯＬ． Ｖ２ Ｎ３, 197506, Ｐ２０９-２１４ * |
| JPN6014024149; ｐｒｏｇｒｅｓｓ ｉｎ ｎｅｕｒｏ-ｐｓｙｃｈｏｐｈａｒｍａｃｏｌｏｇｙ ＆ ｂｉｏｌｏｇｉｃａｌ ｐｓｙｃｈｉａｔｒｙ Ｖｏｌ．１０， Ｎｏ．１, 1986, ｐ．６７-７５ * |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2011011579A (es) | 2012-01-27 |
| WO2010127120A1 (en) | 2010-11-04 |
| AU2010242971A1 (en) | 2011-11-24 |
| US20120115871A1 (en) | 2012-05-10 |
| CA2760527A1 (en) | 2010-11-04 |
| EP2424539A4 (en) | 2012-09-19 |
| JP2014240417A (ja) | 2014-12-25 |
| EP2424539A1 (en) | 2012-03-07 |
| CO6470848A2 (es) | 2012-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111201039B (zh) | 大麻二酚与5-ht2b受体激动剂安非他明的组合治疗癫痫的用途 | |
| Scully Cbe | Drug effects on salivary glands: dry mouth | |
| M Stahl et al. | Serotonergic drugs for depression and beyond | |
| JP2609968B2 (ja) | グリシン／ｎｍｄａ受容体複合体の機能性拮抗剤による情緒障害の治療 | |
| Pezzoli et al. | Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study | |
| CA2893238C (en) | D-methadone for the treatment of psychiatric symptoms | |
| KR102527805B1 (ko) | 부스피론 대사물의 용도 | |
| CN103025332A (zh) | 治疗代谢综合征、2型糖尿病、肥胖或前驱糖尿病的治疗剂 | |
| FI3352735T3 (fi) | Pitkitetysti vapauttavia olantsapiiniformulaatioita | |
| KR20090036114A (ko) | 무스카린성 수용체 ｍ1 길항제를 이용한 심리 질환 치료 방법 | |
| KR20050049476A (ko) | 홍조를 치료하기 위한 레복세틴의 용도 | |
| JP2014240417A (ja) | うつ病を治療する方法 | |
| JPWO2009069828A1 (ja) | パーキンソン病の運動合併症または精神症状を改善する薬剤 | |
| KR20070121032A (ko) | 네포팜 및 그 유사체의 치료학적 용도 | |
| CN106413714A (zh) | (r)‑吡吲哚及其药学上可接受的盐的药学用途 | |
| Strecker et al. | Parkinson's disease: emerging pharmacotherapy | |
| CZ301210B6 (cs) | Použití desoxypeganinu k ošetrování klinické deprese | |
| Srinivasan et al. | Sleep, mood disorders and antidepressants: the melatonergic antidepressant agomelatine offers a new strategy for treatment | |
| Suski et al. | 20 Dopamine agonists | |
| Chaturvedi et al. | Effect of NMDA receptor antagonists in forced swimming test and its modification by antidepressants | |
| JP2020525548A (ja) | 炎症反応を伴う疼痛状態における鎮痛のための末梢限局的二重作用性κおよびδオピオイドアゴニスト | |
| Ram et al. | Pharmacological Approaches in Alcohol Use Disorder-Exploring Off-Label an Emerging Treatments in Clinical and Preclinical Evidence | |
| Fukumoto et al. | and the Mechanisms | |
| Shams et al. | P. 2. b. 001 Water extract of saffron (Crocus sativus) increases brain dopamine and glutamate concentration in the rat | |
| TCA | Antidepressants and Anticonvulsants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130426 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130501 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140617 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20141125 |